Recombinant double mutant heat-labile toxin (National Institute of Allergy and Infectious Diseases)

N/A

Report date: 2022/12/31 17:29:59

Base Information

Drug NameRecombinant double mutant heat-labile toxin (National Institute of Allergy and Infectious Diseases)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant proteinBiologics > Protein drugs > Toxin
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsGastroenteritisEscherichia coli Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesNational Institute Of Allergy And Infectious Diseases (Niaid)
China Registration ClassN/A

Develop Information

Active CompaniesNational Institute Of Allergy And Infectious Diseases (Niaid)
Inactive CompaniesN/A
Active IndicationsEscherichia coli Infections
Inactive IndicationsGastroenteritis

Other Information

ATC CodeN/A
Related LinksN/A